Max Mitteregger and Johan Lund proposed as Board members at LIDDS
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Uppsala, SWEDEN - LIDDS AB (publ) announces today that the Nomination Committee will propose Max Mitteregger and Johan Lund as new members of LIDDS’ Board of Directors.
Max Mitteregger has many years of experience from the financial market, where he worked at Carnegie in Stockholm and New York, and was a co-founder of ABGSC. He has since 2005 been the manager of the hedge fund Gladiator. In connection with the appointment to LIDDS’ Board of Directors, Max Mitteregger will acquire shares at a total value of 4.5 MSEK. It is proposed that this will be done through a directed share issue of 750,000 shares at a subscription price of 6 SEK, subject to the approval of the Annual General Meeting.
Johan Lund has experience from senior roles in the global pharmaceutical industry, for example as Vice President at AstraZeneca, Pfizer and Biogen. Johan has an MD and a PhD from the Karolinska Institute. He currently is a Board member in several listed and private companies. Johan's broad network within various major pharmaceutical companies as well as his scientific knowledge will be an important addition to the board for establishing new collaborations and driving the company pipeline forward.
The Nomination Committee proposes re-election of the Board members David Bejker, Maria Forss, Daniel Lifveredson and Jan Törnell, with Jan Törnell being proposed to continue as chairman. Anders Bjartell and IngaLill Forslund Larsson have declined re-election in order to be able to devote themselves to other commitments.
"Max and Johan will be important reinforcements of LIDDS board with their broad network and experience from both drug development and financing, which will contribute strongly to the company's continued development," says Bengt-Åke Bengtsson, chairman of the Nomination Committee.
"I welcome Max and Johan to our Board and look forward to our future collaboration," says Jan Törnell, chairman of the board. "At the same time, I would like to thank Anders and IngaLill for their wholehearted and very important contribution to LIDDS’ build-up and development in recent years, as the company has evolved from a one-product company to an innovative drug delivery company," he continues. "I hope to have future collaborations with Anders and IngaLill in some form".